Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698425 | Clinical Oncology | 2013 | 7 Pages |
Abstract
RapidArc is better than conventional IMRT in terms of dosimetry and delivery efficiency for high-risk prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.M.C. Poon, M. Kam, C.M. Leung, R. Chau, S. Wong, W.Y. Lee, K.C.W. Wong, B. Yu, A. Chan,